December 31, 2003

News Release: Novamex USA Ltd. Receives $5,000,000 Financing Package Subscription Agreement for its BSE - Mad Cow Disease - Test

VILLE SAINT-LAURENT, Quebec--(BUSINESS WIRE)--Dec. 31, 2003--Novamex USA Ltd. (Pink Sheets: NOVM) is pleased to announce that it has received a subscription agreement from a private trust company for a $5,000,000 financing package. The Investor has agreed to subscribe to a 5 year convertible debenture paying an annual interest of 7%, and convertible into common stock of Novamex USA Ltd. at a price of $1.00 per share. These funds will enable the company to complete staffing requirements and to validate and commercialize its ante mortem diagnostic test kit for BSE . The closing of the subscription is expected to take place on February 16, 2004 Novamex also wishes to report that a Canadian law firm has been appointed to oversee and execute the legal transfer of the worldwide patent no. PCT/FR 02/0078, which was acquired September 3, 2003 from Doctors Jacques A. Mayet and Louis Lery. Patent no. PCT/FR 02/00728 covers a unique testing procedure for a protein (prion) which has been used to develop a test for Bovine Spongiform Encephalopathy, commonly known as "Mad Cow Disease". Unlike existing tests, this test can be performed on living animals.

Under the agreement for the acquisition of the patent, a payment of $50,000 USD has been made and a total of 6,000,000 restricted shares of NOVAMEX USA Ltd. have been issued in favour of Drs. Mayet and Lery.

Novamex USA Ltd. is in the process of having its SEC filings brought up to date. This step will allow the Company to apply for a listing on the OTC BB.

Novamex USA Ltd. is a publicly traded company, currently listed on the Pink Sheets under the symbol NOVM.

DISCLAIMER:

This PRESS RELEASE contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which act contains a safe harbor for forward looking statements. Statements made in connection with initial public offerings, however, are not protected by the safe harbor of the Private Securities Litigation Reform Act of 1995. Nonetheless, the Company believes that investors would be benefited by the cautionary language included in this paragraph. For this purpose any statements contained in this PRESS RELEASE that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "estimate," or "continue" or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within the Company's control. These factors include but are not limited to economic conditions generally and in the industries in which the Company may participate; competition within the Company's chosen industry, including competition from much larger competitors; technological advances, failure by the Company to successfully obtain proper financing, and failure to develop business relationships.

Contacts

Novamex USA Ltd.
Karim Menassa, 514-339-9355


WEBSITE This email address is being protected from spambots. You need JavaScript enabled to view it.